RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)

By afschroeder • July 9, 2025

Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Couselo EM, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai KK, Lebbé C, Gaudy-Marqueste C, Middleton MR, Skolariki A, Samson A, Chesney JA, VanderWalde AM, Zakharia Y, Harrington KJ, Appleton E, Bommareddy PK, Zhu J, Viana M, Hou JW, Coffin RS, Robert C. RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). J Clin Oncol. 2025 Jul 8:101200JCO2501346. doi: 10.1200/JCO-25-01346. Epub ahead of print. PMID: 40627813.

Tags: Hematology/Oncology, Publications

Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

Kumaraswamy A, Hu YM, Yates JA, Zhang C, Rodansky E, Khokhani D, Flores D, Duan Z, Zhang Y, Tabatabaei S, Slottke R, Ye S, Lara[...]

Predicting subjective sleepiness during auditory cognitive testing using voice signaling analysis

Te TT, Boland MR, Ghadimi S, Dzierzewski JM, Alessi C, Martin JL, Kremen S, Bui AAT, Naeim A, Fung CH. Predicting subjective sleepiness during auditory[...]

Feasibility of cognitive testing and ecological momentary assessments using smartphones in middle aged and older adults with insomnia

Ghadimi S, Ereso J, Kaula AJ, Taptiklis N, Cormack F, Alessi C, Martin JL, Dzierzewski JM, Naeim A, Kremen S, Te T, Fung CH. Feasibility[...]